CYP4F3 and hematologic disorder: A large number of treatments administered in hematologic malignancy patients, including chemotherapy agents, are metabolized through the cytochrome P-450 (CYP) pathway, with potential important interactions with agents, such as voriconazole and posaconazole, both strong inhibitors of CYP3A4.